ビオフェルミン製薬(株)の貸借残高情報
| 主市場 | 業種 | 証券コード/EDINET | 英名称 |
|---|---|---|---|
| 東証1部 | 医薬品 | 4517/E00960 | BIOFERMIN PHARMACEUTICAL CO.,LTD. |
| 公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
|---|---|---|---|---|---|---|---|---|---|
| 2018/05/11 | 日証協 | 10,300株 | +35.53% | 2,700株 | +2600% | 15,414株 | +1.31% | 300株 | +200% |
| 2018/05/02 | 日証協 | 7,600株 | +1.33% | 100株 | -91.67% | 15,214株 | 0% | 100株 | 0% |
| 2018/04/27 | 日証協 | 7,500株 | 0% | 1,200株 | +200% | 15,214株 | -1.3% | 0株 | -100% |
| 2018/04/20 | 日証協 | 7,500株 | +5.63% | 400株 | -42.86% | 15,414株 | +1.31% | 200株 | 0% |
| 2018/04/13 | 日証協 | 7,100株 | +10.94% | 700株 | -75.86% | 15,214株 | +23.55% | 200株 | -95.36% |
| 2018/04/06 | 日証協 | 6,400株 | -29.67% | 2,900株 | +190% | 12,314株 | -2.32% | 4,307株 | +207.64% |
| 2018/03/30 | 日証協 | 9,100株 | -43.83% | 1,000株 | +233.33% | 12,606株 | -28.43% | 1,400株 | +366.67% |
| 2018/03/23 | 日証協 | 16,200株 | +8% | 300株 | -95.08% | 17,614株 | +6.66% | 300株 | -94% |
| 2018/03/16 | 日証協 | 15,000株 | +44.23% | 6,100株 | +771.43% | 16,514株 | +12.23% | 5,000株 | +316.67% |
| 2018/03/09 | 日証協 | 10,400株 | +5.05% | 700株 | -74.07% | 14,714株 | +0.68% | 1,200株 | 0% |
| 2018/03/02 | 日証協 | 9,900株 | +2.06% | 2,700株 | -56.45% | 14,614株 | +6.56% | 1,200株 | +32.74% |
| 2018/02/23 | 日証協 | 9,700株 | +11.49% | 6,200株 | +31.91% | 13,714株 | +3.82% | 904株 | -52.42% |
| 2018/02/16 | 日証協 | 8,700株 | +32.56% | 4,700株 | +840% | 13,210株 | +12.81% | 1,900株 | +63.37% |
| 2018/02/09 | 日証協 | 6,563株 | -46.48% | 500株 | -87.38% | 11,710株 | -13.32% | 1,163株 | -41.85% |
| 2018/02/02 | 日証協 | 12,263株 | -18.52% | 3,963株 | -9.11% | 13,510株 | -12.1% | 2,000株 | +7.53% |
| 2018/01/26 | 日証協 | 15,050株 | +14.1% | 4,360株 | -16.15% | 15,370株 | +12.93% | 1,860株 | -28.46% |
| 2018/01/19 | 日証協 | 13,190株 | +21.12% | 5,200株 | -39.53% | 13,610株 | +23.57% | 2,600株 | -18.75% |
| 2018/01/12 | 日証協 | 10,890株 | +25.32% | 8,600株 | 0% | 11,014株 | -53.15% | 3,200株 | +1468.63% |
| 2018/01/05 | 日証協 | 8,690株 | -36.52% | 0株 | -100% | 23,510株 | -8.56% | 204株 | -98.65% |
※株式分割は考慮していませんのでご注意ください。